TSC2/PKD1 contiguous gene syndrome, with emphasis on a case with an atypical mild polycystic kidney phenotype and a novel genetic variant

Rakowski, 2006, Renal manifestations of tuberous sclerosis complex: incidence, prognosis, and predictive factors, Kidney Int, 70, 1777, 10.1038/sj.ki.5001853 Curatolo, 2013 Martignoni G, Bonetti F, Pea M, Tardanico R, Brunelli M, Eble JN. Renal disease in adults with TSC2/PKD1 contiguous gene syndrome. Am J Surg Pathol. 2002;26(2):198-205. https://doi.org/10.1097%2F00000478-200202000-00006 Longa, 1997, A large TSC2 and PKD1 gene deletion is associated with renal and extrarenal signs of autosomal dominant polycystic kidney disease, Nephrol Dial Transpl, 12, 1900, 10.1093/ndt/12.9.1900 Chen, 2001, Tuberous sclerosis complex with an unruptured intracranial aneurysm: manifestations of contiguous gene syndrome, Interv Neuroradiol, 7, 337, 10.1177/159101990100700410 Sampson, 1997, Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene, Am J Hum Genet, 61, 843, 10.1086/514888 Torra, 1998, Facilitated diagnosis of the contiguous gene syndrome: tuberous sclerosis and polycystic kidneys by means of haplotype studies, Am J Kidney Dis, 31, 1038, 10.1053/ajkd.1998.v31.pm9631851 Dauwerse, 2002, Acrofacial dysostosis in a patient with the TSC2-PKD1 contiguous gene syndrome, J Med Genet, 39, 134, 10.1136/jmg.39.2.136 Smulders, 2003, Large deletion causing the TSC2;PKD1 contiguous gene syndrome without infantile polycystic disease, J Med Genet, 40, 10.1136/jmg.40.2.e17 Kozlowski, 2007, Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype–phenotype correlations, Hum Genet, 121, 389, 10.1007/s00439-006-0308-9 Consugar, 2008, Characterization of large rearrangements in autosomal dominant polycystic kidney disease and the PKD1/TSC2 contiguous gene syndrome, Kidney Int, 74, 1468, 10.1038/ki.2008.485 Boehm, 2007, Gross genomic rearrangement involving the TSC2-PKD1 contiguous deletion syndrome: characterization of the deletion event by quantitative polymerase chain reaction deletion assay, Am J Kidney Dis, 49, 10.1053/j.ajkd.2006.10.024 Kacerovska, 2009, TSC2/PKD1 contiguous gene syndrome: a report of 2 cases with emphasis on dermatopathologic findings, Am J Dermatopathol, 31, 532, 10.1097/DAD.0b013e3181970e44 Oyazato, 2011, Molecular analysis of TSC2/PKD1 contiguous gene deletion syndrome, Kobe J Med Sci, 57 Ismail, 2014, Two novel gross deletions of TSC2 in Malaysian patients with tuberous sclerosis complex and TSC2/PKD1 contiguous deletion syndrome, Jpn J Clin Oncol, 44, 506, 10.1093/jjco/hyu024 Furlano, 2017, Sangrado de angiomiolipoma renal en paciente con síndrome de genes contiguos (TSC2/PKD1) tras 17 años de tratamiento renal sustitutivo, Nefrología, 37, 87, 10.1016/j.nefro.2016.04.007 Northrup, 2013, Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference, Pediatr Neurol, 49, 243, 10.1016/j.pediatrneurol.2013.08.001 Pei, 2015, Imaging-based diagnosis of autosomal dominant polycystic kidney disease, J Am Soc Nephrol, 26, 746, 10.1681/ASN.2014030297 Firth, 2009, DECIPHER: database of chromosomal imbalance and phenotype in humans using ensembl resources, Am J Hum Genet, 84, 524, 10.1016/j.ajhg.2009.03.010 MacDonald, 2014, The database of genomic variants: a curated collection of structural variation in the human genome, Nucleic Acids Res, 42, 986, 10.1093/nar/gkt958 Cramer, 2015, Cystic kidney disease: a primer, Adv Chronic Kidney Dis, 22, 297, 10.1053/j.ackd.2015.04.001 Chebib, 2018, Recent advances in the management of autosomal dominant polycystic kidney disease, Clin J Am Soc Nephrol, 13, 1765LP, 10.2215/CJN.03960318 Müller, 2018, Management of autosomal-dominant polycystic kidney disease—state-of-the-art, Clin Kidney J, 11, i2, 10.1093/ckj/sfy103 Lanktree, 2017, New treatment paradigms for ADPKD: moving towards precision medicine, Nat Rev Nephrol, 13, 750, 10.1038/nrneph.2017.127 Rysz, 2016, Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease, Expert Opin Pharmacother, 17, 2049, 10.1080/14656566.2016.1232394 Masyuk, 2007, Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3′,5′-cyclic monophosphate, Gastroenterology, 132, 1104, 10.1053/j.gastro.2006.12.039 Sun, 2011, Drug discovery for polycystic kidney disease, Acta Pharmacol Sin, 32, 805, 10.1038/aps.2011.29 Artuso, 2011, Investigation of modifier genes within copy number variations in Rett syndrome, J Hum Genet, 56, 508, 10.1038/jhg.2011.50 Uhlén, 2015, Tissue-based map of the human proteome, Science (80-), 347, 1260419, 10.1126/science.1260419 2017